The mid-December approval of a gene therapy packaged inside an adeno-associated virus (AAV) vector to treat patients with certain inherited retinal diseases capped several decades of effort to bring in vivo gene therapy to patients. It was also the cherry on top of an impressive year…

Click here to original publication.

Fonte: NATURE BIOTECHNOLOGY VOLUME 36 NUMBER 2 FEBRUARY 2018 131